ApconiX Return Over 80% of hERG Screening Data to Clients Within One Week

Why is Time Critical to hERG Screening Data?

ApconiX has worked hard to optimise our processes and is now returning over 80% of hERG screening data back to clients within one week of compound receipt.  This allows critical decisions to be made in medicinal chemistry on a full dataset of compound properties, avoiding mistakes and delays in compound selection.

All hERG data is reported within two weeks. We always work with our clients to ensure we are providing a service that is flexible and fits within their project time lines.

The testing and analysis is carried out by expert electrophysiologists.  The strength of the ApconiX team is being able to deliver well informed, up-to-date advice that goes far beyond the data.  We aim to help our clients make the best possible decisions and speaking to the scientists is part of the service.

Why is hERG Important?

Inhibition of potassium currents through the hERG ion channel is linked to a potentially fatal cardiac arrhythmia long QT syndrome and Torsades de Pointes.  During drug discovery, potential drug molecules are therefore screened to eliminate those that inhibit hERG.  This optimisation of chemical leads based on data feedback is an iterative process and an integral part of the design-make-test (DMT) cycle.  Today, hERG assays are frequently outsourced to specialist external providers.  However, the typical 3-4-week turnaround time often fails to align with decision-making, adversely impacting the research team’s “design-make-test” cycle.

Dr Stuart Best, Redx Pharma:  “ApconiX has provided hERG data to Redx Pharma from June 2016 to help support our discovery projects. Data turnaround times over this period have been rapid (under 1 week) and this has been critical in progressing projects quickly; outsourcing the assay with this turn-around has had no impact on our “design-make-test” cycle times.  

Additionally, ApconiX’s approach is very collaborative providing expert advice on these data as part of their service. Another vital component to this screening is flexibility over compound numbers which enables us to maintain progress during the peaks and troughs of compound supply and prevents delays which can occur if you have to wait to reach a trigger point for submission of an assay.”

If you would like to take advantage of our rapid turnaround times, please get in touch at michael.morton@apconix.com

By |2018-07-19T16:25:00+00:00March 5th, 2018|Ion Channels|Comments Off on ApconiX Return Over 80% of hERG Screening Data to Clients Within One Week

About the Author:

Dr Michael Morton, PhD, Director and Cofounder, ApconiX, UK, an integrated toxicology and ion channel company that brings together a team of world-renowned nonclinical safety experts with over 400 years of drug discovery and development experience. Mike graduated from the University of Wolverhampton with a degree in Biomedical Sciences and then aspiration to work in hospital pathology. Having finished his Sandwich placement in Clinical Biochemistry at Sandwell Hospital and Mike subsequently gained a MSc in Clinical Biochemistry from the University of Manchester and carried out research into porphyrin metabolism. Moving to the University of Leeds, Mike completed his PhD in Pharmacology at researching adenosine receptor expression in the rat kidney . Mike was introduced to ion channels as a Post-Doc at Leeds and Yale University, patching with the likes of Fred Sigworth and Steve Hebert, then joined the Global Ion Channel Initiative at AstraZeneca. Mike worked at AstraZeneca for eight years before founding ApconiX with Professor Ruth Roberts and Dr Richard Knight. Mike has a serious passion for ion channels. And he’s very good at them . He is a serious scientist (with a serious sense of humour) who wants to make sure that every customer understands the consequences of the results he obtains and works with his colleagues to ensure a better decision is made on drug safety.